Immune Design to Present at 3rd Annual Cancer Immunotherapy Conference

        Print
| Source: Immune Design

SEATTLE, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Immune Design today announced that the company will be presenting at the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, October 4, at 3:15 p.m. ET, at the New York Academy of Medicine. Immune Design's President and Chief Executive Officer, Carlos Paya, M.D., Ph.D., will provide an overview of the Company's immunotherapy platform technologies and planned product pipeline.

A webcast of the company's presentation at the MD Becker Conference will be available live on the conferences website at www.regonline.com/mdb2012 and archived through the News page in the Resources section of the Immune Design website at www.immunedesign.com.

About the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference

"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.

About Immune Design Corp.

Immune Design is a privately held biotechnology company based in Seattle, Washington and formed in 2008 to bring together some of the world's leaders in the field of molecular immunology to develop therapeutic vaccines for the treatment of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms.

Additional information can be found on the company's website at www.immunedesign.com.

The Immune Design logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13428

Immune Design Corp.